A detailed history of Moran Wealth Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Moran Wealth Management, LLC holds 15,030 shares of PTGX stock, worth $590,679. This represents 0.02% of its overall portfolio holdings.

Number of Shares
15,030
Previous 11,780 27.59%
Holding current value
$590,679
Previous $408,000 65.44%
% of portfolio
0.02%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$33.72 - $47.33 $109,590 - $153,822
3,250 Added 27.59%
15,030 $675,000
Q2 2024

Aug 13, 2024

BUY
$24.66 - $34.8 $25,745 - $36,331
1,044 Added 9.72%
11,780 $408,000
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $233,937 - $345,162
10,736 New
10,736 $310,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Moran Wealth Management, LLC Portfolio

Follow Moran Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moran Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moran Wealth Management, LLC with notifications on news.